Fig. 2.

ROCK inhibition normalizes LEC and BEC junctions and reverses lymphedema. (A) VE-cadherin staining of engineered lymphatics exposed to IL-2 with or without Y27632. (B) Percent zipper junction in engineered lymphatics exposed to IL-2 with or without Y27632 (n = 8, N = 3). (C) Percent lymphatic drainage with Y27632 (BODIPY-C₁₆ fatty acid drainage) (N = 4). (D) Percent lymphatic drainage with Y27632, Fasudil, and Ripasudil (BODIPY-C₁₆ fatty acid drainage) (N = 5). (E) Dye-leakage-based permeability assays and VE-cadherin images of engineered blood vessels. (F) The permeability coefficient of the engineered blood vessels in inflammation with or without Y27632 (N = 3). (G) Effects of ROCK inhibition on LEC and BEC junctions. (H) Tail volume change with Y27632 in a murine lymphedema model (N = 5). (I) Tail volume change with Y27632 in the lymphedema model when swelling is peaked in the control group (N = 5). (J) Representative images of tails with Y27632 treatment. [Scale bars (A and E, Lower), 50 μm; Scale bars (E, Upper), 200 μm; Scale bars (J), 5 mm.] *P < 0.05 indicates statistical significance.